Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mesothelioma | 16 | 2017 | 311 | 3.460 |
Why?
|
Pleural Neoplasms | 9 | 2016 | 188 | 2.170 |
Why?
|
Lung Neoplasms | 23 | 2017 | 2262 | 1.880 |
Why?
|
Graft Rejection | 9 | 2017 | 1065 | 1.520 |
Why?
|
Immunohistochemistry | 12 | 2017 | 1753 | 1.170 |
Why?
|
Heart Transplantation | 8 | 2017 | 705 | 1.060 |
Why?
|
Lung | 10 | 2017 | 1170 | 1.060 |
Why?
|
Lung Transplantation | 3 | 2016 | 175 | 0.940 |
Why?
|
Complement C4b | 2 | 2017 | 35 | 0.940 |
Why?
|
Proto-Oncogene Proteins c-met | 8 | 2014 | 199 | 0.890 |
Why?
|
Biomarkers, Tumor | 12 | 2017 | 1464 | 0.880 |
Why?
|
Adenocarcinoma | 8 | 2017 | 1169 | 0.810 |
Why?
|
Diagnosis, Differential | 11 | 2017 | 1565 | 0.750 |
Why?
|
Myocardium | 5 | 2017 | 529 | 0.710 |
Why?
|
Hypertension, Pulmonary | 7 | 2017 | 346 | 0.690 |
Why?
|
Paxillin | 4 | 2013 | 59 | 0.660 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2013 | 1075 | 0.610 |
Why?
|
Epithelium | 3 | 2015 | 319 | 0.590 |
Why?
|
Pleura | 2 | 2013 | 30 | 0.580 |
Why?
|
Forecasting | 1 | 2017 | 304 | 0.560 |
Why?
|
Arrhythmogenic Right Ventricular Dysplasia | 1 | 2015 | 10 | 0.540 |
Why?
|
Epoprostenol | 2 | 2012 | 46 | 0.530 |
Why?
|
Respiratory Mucosa | 1 | 2016 | 88 | 0.530 |
Why?
|
Fibrosis | 3 | 2017 | 203 | 0.500 |
Why?
|
Pleurisy | 1 | 2013 | 4 | 0.490 |
Why?
|
Glucose Transporter Type 1 | 1 | 2013 | 20 | 0.480 |
Why?
|
PAX5 Transcription Factor | 2 | 2010 | 32 | 0.470 |
Why?
|
Hyperplasia | 1 | 2013 | 148 | 0.470 |
Why?
|
Humans | 73 | 2018 | 86643 | 0.470 |
Why?
|
Idiopathic Interstitial Pneumonias | 1 | 2012 | 28 | 0.440 |
Why?
|
Pathology, Clinical | 1 | 2012 | 33 | 0.430 |
Why?
|
Postoperative Complications | 4 | 2016 | 2207 | 0.430 |
Why?
|
Pulmonary Medicine | 1 | 2012 | 46 | 0.420 |
Why?
|
Sarcoma | 1 | 2013 | 215 | 0.420 |
Why?
|
Connective Tissue Diseases | 1 | 2012 | 67 | 0.410 |
Why?
|
Small Cell Lung Carcinoma | 4 | 2013 | 98 | 0.370 |
Why?
|
Biopsy | 8 | 2017 | 1163 | 0.360 |
Why?
|
Pathology, Surgical | 1 | 2009 | 12 | 0.350 |
Why?
|
Prognosis | 8 | 2017 | 3679 | 0.340 |
Why?
|
Neuroendocrine Tumors | 1 | 2010 | 105 | 0.340 |
Why?
|
Lymphangiogenesis | 1 | 2008 | 38 | 0.330 |
Why?
|
Lymphatic Metastasis | 2 | 2015 | 486 | 0.320 |
Why?
|
Middle Aged | 26 | 2018 | 25028 | 0.320 |
Why?
|
Peritoneal Neoplasms | 1 | 2009 | 177 | 0.310 |
Why?
|
Lung Diseases | 1 | 2009 | 263 | 0.300 |
Why?
|
Practice Patterns, Physicians' | 1 | 2012 | 582 | 0.290 |
Why?
|
Cell Proliferation | 11 | 2014 | 1578 | 0.290 |
Why?
|
Alveolitis, Extrinsic Allergic | 2 | 2017 | 34 | 0.290 |
Why?
|
Male | 34 | 2018 | 40965 | 0.280 |
Why?
|
Retrospective Studies | 9 | 2018 | 8489 | 0.280 |
Why?
|
Antibodies | 1 | 2008 | 350 | 0.280 |
Why?
|
Peptide Fragments | 1 | 2008 | 460 | 0.280 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2016 | 63 | 0.270 |
Why?
|
Epithelioid Cells | 2 | 2016 | 13 | 0.270 |
Why?
|
Female | 32 | 2018 | 44532 | 0.260 |
Why?
|
Tomography, X-Ray Computed | 6 | 2017 | 2601 | 0.260 |
Why?
|
Adult | 19 | 2018 | 25648 | 0.260 |
Why?
|
Lung Diseases, Interstitial | 2 | 2018 | 235 | 0.250 |
Why?
|
Tumor Suppressor Proteins | 2 | 2016 | 279 | 0.240 |
Why?
|
Aged | 18 | 2018 | 18415 | 0.230 |
Why?
|
Receptor, EphB4 | 2 | 2013 | 24 | 0.230 |
Why?
|
Aged, 80 and over | 10 | 2016 | 6509 | 0.220 |
Why?
|
International Cooperation | 2 | 2013 | 127 | 0.220 |
Why?
|
Tissue Array Analysis | 5 | 2016 | 124 | 0.210 |
Why?
|
Cardiomyopathies | 2 | 2015 | 240 | 0.210 |
Why?
|
Cell Line, Tumor | 12 | 2016 | 2426 | 0.210 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2013 | 153 | 0.210 |
Why?
|
S100 Proteins | 2 | 2012 | 50 | 0.200 |
Why?
|
Focal Adhesions | 2 | 2013 | 69 | 0.200 |
Why?
|
Endothelium | 2 | 2013 | 59 | 0.190 |
Why?
|
Mitochondria | 2 | 2016 | 535 | 0.190 |
Why?
|
Muscle, Smooth, Vascular | 2 | 2012 | 231 | 0.190 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2010 | 20 | 0.190 |
Why?
|
Receptors, Lysosphingolipid | 2 | 2010 | 36 | 0.180 |
Why?
|
Asthma | 3 | 2013 | 955 | 0.180 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2016 | 348 | 0.180 |
Why?
|
Neoplasm Metastasis | 2 | 2014 | 1056 | 0.180 |
Why?
|
Phosphorylation | 6 | 2014 | 1106 | 0.180 |
Why?
|
Indoles | 4 | 2013 | 318 | 0.170 |
Why?
|
Follow-Up Studies | 4 | 2017 | 3640 | 0.170 |
Why?
|
Survival Analysis | 3 | 2017 | 1538 | 0.160 |
Why?
|
Autopsy | 3 | 2013 | 116 | 0.160 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2013 | 383 | 0.160 |
Why?
|
Bronchiolitis Obliterans | 2 | 2016 | 31 | 0.160 |
Why?
|
Apoptosis | 7 | 2014 | 1683 | 0.160 |
Why?
|
Protein Kinase Inhibitors | 3 | 2013 | 589 | 0.160 |
Why?
|
Idiopathic Pulmonary Fibrosis | 2 | 2017 | 165 | 0.150 |
Why?
|
Cytodiagnosis | 1 | 2017 | 42 | 0.150 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 859 | 0.150 |
Why?
|
Pneumonectomy | 2 | 2016 | 196 | 0.150 |
Why?
|
Public Opinion | 1 | 2017 | 43 | 0.150 |
Why?
|
Defibrillators, Implantable | 2 | 2016 | 129 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2013 | 1197 | 0.150 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 11 | 0.150 |
Why?
|
Allografts | 1 | 2017 | 172 | 0.140 |
Why?
|
Orbital Myositis | 1 | 2016 | 1 | 0.140 |
Why?
|
Gene Dosage | 6 | 2013 | 207 | 0.140 |
Why?
|
DNA Topoisomerases, Type I | 2 | 2013 | 23 | 0.140 |
Why?
|
Cytokines | 2 | 2012 | 776 | 0.140 |
Why?
|
Kidney Neoplasms | 2 | 2014 | 621 | 0.140 |
Why?
|
Pulmonary Alveoli | 1 | 2016 | 71 | 0.140 |
Why?
|
Fractals | 1 | 2016 | 42 | 0.140 |
Why?
|
Primary Graft Dysfunction | 1 | 2016 | 27 | 0.140 |
Why?
|
Paired Box Transcription Factors | 2 | 2013 | 50 | 0.140 |
Why?
|
Transplantation, Homologous | 2 | 2016 | 996 | 0.140 |
Why?
|
Niacinamide | 2 | 2013 | 116 | 0.140 |
Why?
|
Antihypertensive Agents | 2 | 2010 | 521 | 0.130 |
Why?
|
Myocarditis | 1 | 2016 | 50 | 0.130 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2014 | 182 | 0.130 |
Why?
|
Consensus | 1 | 2017 | 335 | 0.130 |
Why?
|
Genes, Dominant | 1 | 2015 | 117 | 0.130 |
Why?
|
Sensitivity and Specificity | 3 | 2017 | 1991 | 0.130 |
Why?
|
Death, Sudden, Cardiac | 1 | 2015 | 45 | 0.130 |
Why?
|
Bronchoscopy | 2 | 2013 | 152 | 0.130 |
Why?
|
Autoimmune Diseases | 1 | 2017 | 241 | 0.130 |
Why?
|
Carcinoma | 3 | 2013 | 436 | 0.130 |
Why?
|
Disease Models, Animal | 6 | 2013 | 2232 | 0.130 |
Why?
|
Toxoplasmosis | 1 | 2015 | 64 | 0.130 |
Why?
|
Mice | 13 | 2015 | 11352 | 0.130 |
Why?
|
Radiography, Thoracic | 1 | 2016 | 320 | 0.120 |
Why?
|
Pleural Effusion, Malignant | 1 | 2014 | 15 | 0.120 |
Why?
|
Carbonic Anhydrases | 1 | 2014 | 15 | 0.120 |
Why?
|
Terminology as Topic | 1 | 2016 | 217 | 0.120 |
Why?
|
Staphylococcal Infections | 2 | 2008 | 255 | 0.120 |
Why?
|
RNA, Small Interfering | 4 | 2013 | 547 | 0.120 |
Why?
|
Survival Rate | 2 | 2016 | 1863 | 0.120 |
Why?
|
Surgical Wound Infection | 1 | 2016 | 184 | 0.120 |
Why?
|
Arrhythmias, Cardiac | 1 | 2015 | 187 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 3 | 2016 | 860 | 0.120 |
Why?
|
GATA3 Transcription Factor | 1 | 2013 | 48 | 0.120 |
Why?
|
Cell Cycle | 2 | 2014 | 502 | 0.120 |
Why?
|
Pulmonary Artery | 2 | 2017 | 306 | 0.120 |
Why?
|
Indazoles | 1 | 2013 | 68 | 0.120 |
Why?
|
Carcinoma, Small Cell | 1 | 2013 | 134 | 0.110 |
Why?
|
Mitochondrial Dynamics | 1 | 2013 | 53 | 0.110 |
Why?
|
Cooperative Behavior | 1 | 2013 | 174 | 0.110 |
Why?
|
Hospitalization | 1 | 2018 | 849 | 0.110 |
Why?
|
Diffusion of Innovation | 1 | 2013 | 71 | 0.110 |
Why?
|
Forkhead Transcription Factors | 1 | 2013 | 166 | 0.110 |
Why?
|
Antineoplastic Agents | 2 | 2014 | 2360 | 0.110 |
Why?
|
Sarcoidosis, Pulmonary | 1 | 2012 | 17 | 0.110 |
Why?
|
Lymphatic Vessels | 1 | 2013 | 68 | 0.110 |
Why?
|
Amyloidosis | 1 | 2014 | 115 | 0.110 |
Why?
|
Antigens, Neoplasm | 1 | 2014 | 325 | 0.110 |
Why?
|
Oxidative Stress | 2 | 2012 | 447 | 0.110 |
Why?
|
Bronchi | 1 | 2013 | 229 | 0.110 |
Why?
|
Gene Expression | 2 | 2013 | 1284 | 0.110 |
Why?
|
Thoracic Surgical Procedures | 1 | 2012 | 44 | 0.110 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2013 | 164 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2014 | 458 | 0.100 |
Why?
|
Cell Survival | 5 | 2013 | 969 | 0.100 |
Why?
|
Gene Expression Profiling | 3 | 2013 | 1384 | 0.100 |
Why?
|
Neoplasm Staging | 3 | 2016 | 1939 | 0.100 |
Why?
|
Schools, Medical | 1 | 2013 | 123 | 0.100 |
Why?
|
Animals | 16 | 2015 | 26582 | 0.100 |
Why?
|
Piperazines | 3 | 2013 | 272 | 0.100 |
Why?
|
Mutation | 7 | 2013 | 3968 | 0.100 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2012 | 87 | 0.100 |
Why?
|
Hypocalcemia | 1 | 2011 | 41 | 0.100 |
Why?
|
Methicillin Resistance | 2 | 2008 | 32 | 0.100 |
Why?
|
Immunoblotting | 4 | 2012 | 268 | 0.100 |
Why?
|
Sulfonamides | 3 | 2013 | 300 | 0.100 |
Why?
|
Tissue Banks | 1 | 2011 | 16 | 0.100 |
Why?
|
Plasma Exchange | 1 | 2011 | 29 | 0.100 |
Why?
|
Catheter Ablation | 1 | 2013 | 233 | 0.100 |
Why?
|
Thoracic Neoplasms | 1 | 2011 | 64 | 0.090 |
Why?
|
Pulmonary Fibrosis | 1 | 2012 | 123 | 0.090 |
Why?
|
Urothelium | 1 | 2011 | 70 | 0.090 |
Why?
|
Vasodilation | 1 | 2010 | 96 | 0.090 |
Why?
|
Receptor, EphA2 | 1 | 2010 | 6 | 0.090 |
Why?
|
Mitochondria, Muscle | 1 | 2010 | 26 | 0.090 |
Why?
|
Surveys and Questionnaires | 3 | 2013 | 2501 | 0.090 |
Why?
|
Fatal Outcome | 4 | 2016 | 293 | 0.090 |
Why?
|
Azathioprine | 1 | 2010 | 125 | 0.090 |
Why?
|
Apolipoproteins E | 1 | 2010 | 129 | 0.090 |
Why?
|
Lung Injury | 1 | 2010 | 47 | 0.090 |
Why?
|
Carcinoma, Renal Cell | 1 | 2014 | 426 | 0.090 |
Why?
|
Esophageal Neoplasms | 1 | 2012 | 321 | 0.090 |
Why?
|
Blood-Air Barrier | 1 | 2009 | 6 | 0.090 |
Why?
|
Autoantibodies | 1 | 2011 | 267 | 0.090 |
Why?
|
Simvastatin | 1 | 2010 | 106 | 0.090 |
Why?
|
Hemosiderosis | 1 | 2009 | 3 | 0.090 |
Why?
|
Pulmonary Alveolar Proteinosis | 1 | 2009 | 4 | 0.090 |
Why?
|
Education, Medical | 1 | 2013 | 233 | 0.090 |
Why?
|
Scleroderma, Systemic | 1 | 2010 | 43 | 0.090 |
Why?
|
HLA Antigens | 1 | 2011 | 232 | 0.090 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2012 | 1076 | 0.090 |
Why?
|
Epigenesis, Genetic | 2 | 2011 | 479 | 0.090 |
Why?
|
Sirolimus | 1 | 2010 | 169 | 0.090 |
Why?
|
Superoxide Dismutase | 1 | 2010 | 177 | 0.090 |
Why?
|
Biomarkers | 3 | 2012 | 1718 | 0.090 |
Why?
|
Mice, Inbred C57BL | 6 | 2012 | 3092 | 0.090 |
Why?
|
Calcinosis | 1 | 2010 | 224 | 0.090 |
Why?
|
Cardiomyopathy, Hypertrophic, Familial | 1 | 2008 | 4 | 0.090 |
Why?
|
Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2008 | 44 | 0.080 |
Why?
|
Radiation Injuries | 1 | 2010 | 155 | 0.080 |
Why?
|
Paraganglioma, Extra-Adrenal | 1 | 2008 | 12 | 0.080 |
Why?
|
Tacrolimus | 1 | 2010 | 373 | 0.080 |
Why?
|
Osteogenesis | 1 | 2010 | 242 | 0.080 |
Why?
|
Skull Neoplasms | 1 | 2008 | 30 | 0.080 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2008 | 8 | 0.080 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 78 | 0.080 |
Why?
|
Urinary Bladder | 1 | 2011 | 246 | 0.080 |
Why?
|
Child, Preschool | 2 | 2012 | 3612 | 0.080 |
Why?
|
Islets of Langerhans | 1 | 2012 | 544 | 0.080 |
Why?
|
Vesicular Transport Proteins | 1 | 2008 | 63 | 0.080 |
Why?
|
Cell Movement | 4 | 2014 | 758 | 0.080 |
Why?
|
Tumor Burden | 3 | 2015 | 289 | 0.080 |
Why?
|
Ventricular Fibrillation | 1 | 2008 | 65 | 0.080 |
Why?
|
Central Nervous System Neoplasms | 1 | 2009 | 81 | 0.080 |
Why?
|
Insulin-Secreting Cells | 1 | 2012 | 397 | 0.080 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2008 | 67 | 0.080 |
Why?
|
Ventilators, Mechanical | 1 | 2008 | 33 | 0.080 |
Why?
|
Staphylococcus aureus | 2 | 2008 | 263 | 0.080 |
Why?
|
Temporal Bone | 1 | 2008 | 66 | 0.080 |
Why?
|
Community-Acquired Infections | 1 | 2008 | 63 | 0.080 |
Why?
|
Disease Progression | 2 | 2012 | 1531 | 0.080 |
Why?
|
Endocardium | 1 | 2008 | 76 | 0.080 |
Why?
|
Signal Transduction | 7 | 2013 | 3241 | 0.080 |
Why?
|
Bacterial Toxins | 1 | 2008 | 111 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 379 | 0.080 |
Why?
|
Tissue Distribution | 1 | 2008 | 290 | 0.080 |
Why?
|
Benzenesulfonates | 1 | 2008 | 66 | 0.080 |
Why?
|
Hemodynamics | 2 | 2008 | 710 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2013 | 689 | 0.080 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2009 | 151 | 0.080 |
Why?
|
Staining and Labeling | 1 | 2008 | 165 | 0.080 |
Why?
|
Prospective Studies | 3 | 2016 | 4213 | 0.080 |
Why?
|
Coronary Circulation | 1 | 2008 | 130 | 0.080 |
Why?
|
Skin Diseases | 1 | 2009 | 166 | 0.080 |
Why?
|
Protein Kinase C | 1 | 2008 | 270 | 0.080 |
Why?
|
Gene Expression Regulation | 3 | 2010 | 1920 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2009 | 322 | 0.080 |
Why?
|
Databases, Factual | 1 | 2011 | 814 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 532 | 0.070 |
Why?
|
Medical Oncology | 1 | 2011 | 359 | 0.070 |
Why?
|
Promoter Regions, Genetic | 1 | 2010 | 937 | 0.070 |
Why?
|
Alleles | 1 | 2010 | 1128 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2008 | 407 | 0.070 |
Why?
|
Receptors, Complement 3d | 1 | 2006 | 14 | 0.070 |
Why?
|
Dendritic Cells, Follicular | 1 | 2006 | 20 | 0.070 |
Why?
|
Treatment Outcome | 2 | 2016 | 7993 | 0.070 |
Why?
|
Dexamethasone | 1 | 2007 | 326 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 2271 | 0.070 |
Why?
|
Cell Cycle Proteins | 1 | 2009 | 388 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 378 | 0.070 |
Why?
|
Waterhouse-Friderichsen Syndrome | 1 | 2005 | 2 | 0.070 |
Why?
|
Ribs | 1 | 2006 | 45 | 0.070 |
Why?
|
Pyridines | 1 | 2008 | 310 | 0.070 |
Why?
|
Meningeal Neoplasms | 1 | 2006 | 61 | 0.070 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2005 | 49 | 0.070 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 1036 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2010 | 977 | 0.060 |
Why?
|
Algorithms | 1 | 2013 | 1830 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2018 | 999 | 0.060 |
Why?
|
Quinazolines | 1 | 2006 | 220 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2009 | 696 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2017 | 2705 | 0.060 |
Why?
|
Drug Synergism | 2 | 2014 | 303 | 0.060 |
Why?
|
Granulomatous Disease, Chronic | 1 | 2003 | 8 | 0.060 |
Why?
|
Bone Neoplasms | 1 | 2006 | 322 | 0.060 |
Why?
|
Prevalence | 2 | 2017 | 1239 | 0.060 |
Why?
|
ErbB Receptors | 1 | 2006 | 485 | 0.050 |
Why?
|
Mice, Transgenic | 3 | 2012 | 1540 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2008 | 1376 | 0.050 |
Why?
|
Genomics | 1 | 2008 | 720 | 0.050 |
Why?
|
S100A12 Protein | 2 | 2012 | 10 | 0.050 |
Why?
|
Topoisomerase I Inhibitors | 2 | 2013 | 33 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 2357 | 0.050 |
Why?
|
Mice, Inbred Strains | 2 | 2015 | 307 | 0.050 |
Why?
|
Mice, Nude | 2 | 2014 | 790 | 0.050 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2012 | 273 | 0.050 |
Why?
|
Wound Healing | 2 | 2014 | 344 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2014 | 262 | 0.050 |
Why?
|
Neoplasms | 2 | 2013 | 2898 | 0.050 |
Why?
|
Cisplatin | 2 | 2016 | 612 | 0.050 |
Why?
|
Enzyme Activation | 2 | 2013 | 692 | 0.040 |
Why?
|
Genes, erbB-1 | 2 | 2010 | 16 | 0.040 |
Why?
|
Chicago | 2 | 2017 | 1379 | 0.040 |
Why?
|
Treatment Failure | 2 | 2013 | 285 | 0.040 |
Why?
|
Transfection | 2 | 2010 | 896 | 0.040 |
Why?
|
Rats | 3 | 2010 | 3990 | 0.040 |
Why?
|
Propensity Score | 1 | 2018 | 136 | 0.040 |
Why?
|
DNA Mutational Analysis | 2 | 2010 | 526 | 0.040 |
Why?
|
Time Factors | 3 | 2011 | 5210 | 0.040 |
Why?
|
Phenotype | 2 | 2016 | 2378 | 0.040 |
Why?
|
Neoplasm Invasiveness | 2 | 2010 | 552 | 0.040 |
Why?
|
Cause of Death | 1 | 2018 | 277 | 0.040 |
Why?
|
Gene Silencing | 2 | 2009 | 172 | 0.040 |
Why?
|
Infant | 3 | 2012 | 3046 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 104 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2012 | 2818 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2017 | 238 | 0.030 |
Why?
|
Radiography | 2 | 2012 | 813 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2010 | 1961 | 0.030 |
Why?
|
Atovaquone | 1 | 2015 | 3 | 0.030 |
Why?
|
Glycolysis | 1 | 2016 | 129 | 0.030 |
Why?
|
Observer Variation | 1 | 2017 | 602 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2010 | 1924 | 0.030 |
Why?
|
Mitochondrial Proteins | 1 | 2016 | 123 | 0.030 |
Why?
|
Shock, Cardiogenic | 1 | 2016 | 95 | 0.030 |
Why?
|
Tachycardia, Ventricular | 1 | 2016 | 115 | 0.030 |
Why?
|
Organ Size | 1 | 2016 | 364 | 0.030 |
Why?
|
Pyrrolidinones | 1 | 2014 | 16 | 0.030 |
Why?
|
Listeriosis | 1 | 2015 | 84 | 0.030 |
Why?
|
Listeria monocytogenes | 1 | 2015 | 89 | 0.030 |
Why?
|
Carbonic Anhydrase IX | 1 | 2014 | 11 | 0.030 |
Why?
|
Anti-Infective Agents | 1 | 2015 | 89 | 0.030 |
Why?
|
Logistic Models | 1 | 2018 | 1186 | 0.030 |
Why?
|
Metformin | 1 | 2016 | 128 | 0.030 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 76 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2016 | 468 | 0.030 |
Why?
|
Prealbumin | 1 | 2014 | 34 | 0.030 |
Why?
|
Radiographic Image Enhancement | 1 | 2016 | 462 | 0.030 |
Why?
|
Quinolines | 1 | 2014 | 95 | 0.030 |
Why?
|
Chronic Disease | 1 | 2017 | 971 | 0.030 |
Why?
|
Forkhead Box Protein O1 | 1 | 2013 | 23 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 429 | 0.030 |
Why?
|
Transplantation Tolerance | 1 | 2015 | 130 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2014 | 128 | 0.030 |
Why?
|
Electrocardiography | 1 | 2016 | 478 | 0.030 |
Why?
|
Amyloid | 1 | 2014 | 85 | 0.030 |
Why?
|
Imidazoles | 1 | 2014 | 162 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2013 | 78 | 0.030 |
Why?
|
Comorbidity | 1 | 2017 | 943 | 0.030 |
Why?
|
Recurrence | 1 | 2016 | 1139 | 0.030 |
Why?
|
Camptothecin | 1 | 2013 | 189 | 0.030 |
Why?
|
Receptor for Advanced Glycation End Products | 1 | 2012 | 17 | 0.030 |
Why?
|
Immune Tolerance | 1 | 2015 | 337 | 0.030 |
Why?
|
Pancreatic Hormones | 1 | 2012 | 15 | 0.030 |
Why?
|
Perioperative Period | 1 | 2012 | 25 | 0.030 |
Why?
|
Pancreas, Exocrine | 1 | 2012 | 18 | 0.030 |
Why?
|
Paraffin Embedding | 1 | 2012 | 78 | 0.030 |
Why?
|
In Situ Nick-End Labeling | 1 | 2012 | 121 | 0.030 |
Why?
|
China | 1 | 2013 | 228 | 0.030 |
Why?
|
Carcinoma, Large Cell | 1 | 2012 | 39 | 0.030 |
Why?
|
Cell Count | 1 | 2012 | 195 | 0.030 |
Why?
|
Barrett Esophagus | 1 | 2012 | 93 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2012 | 303 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 1673 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2012 | 316 | 0.030 |
Why?
|
Receptors, Immunologic | 1 | 2012 | 135 | 0.030 |
Why?
|
Pyrimidines | 1 | 2014 | 370 | 0.030 |
Why?
|
Graft Survival | 1 | 2015 | 884 | 0.030 |
Why?
|
Paclitaxel | 1 | 2013 | 460 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2013 | 615 | 0.020 |
Why?
|
Vascular Surgical Procedures | 1 | 2012 | 148 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2013 | 296 | 0.020 |
Why?
|
Papilloma | 1 | 2011 | 22 | 0.020 |
Why?
|
Echocardiography | 1 | 2016 | 911 | 0.020 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2010 | 65 | 0.020 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2011 | 97 | 0.020 |
Why?
|
Rats, Mutant Strains | 1 | 2010 | 23 | 0.020 |
Why?
|
Hepatocyte Growth Factor | 1 | 2011 | 84 | 0.020 |
Why?
|
Bronchoalveolar Lavage | 1 | 2010 | 26 | 0.020 |
Why?
|
New York City | 1 | 2010 | 59 | 0.020 |
Why?
|
Biomimetics | 1 | 2010 | 29 | 0.020 |
Why?
|
Hyaluronan Receptors | 1 | 2010 | 36 | 0.020 |
Why?
|
Radiation Pneumonitis | 1 | 2010 | 21 | 0.020 |
Why?
|
NADPH Oxidases | 1 | 2010 | 81 | 0.020 |
Why?
|
Peptides | 1 | 2013 | 639 | 0.020 |
Why?
|
Infant, Premature | 1 | 2012 | 290 | 0.020 |
Why?
|
Drug Inverse Agonism | 1 | 2009 | 3 | 0.020 |
Why?
|
Protein Interaction Mapping | 1 | 2010 | 82 | 0.020 |
Why?
|
Drug Administration Routes | 1 | 2009 | 19 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 329 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 2062 | 0.020 |
Why?
|
ras Proteins | 1 | 2010 | 128 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2010 | 154 | 0.020 |
Why?
|
Body Fluids | 1 | 2009 | 36 | 0.020 |
Why?
|
Hydrogen Peroxide | 1 | 2010 | 158 | 0.020 |
Why?
|
Up-Regulation | 1 | 2012 | 712 | 0.020 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2010 | 132 | 0.020 |
Why?
|
Thiophenes | 1 | 2009 | 48 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2010 | 179 | 0.020 |
Why?
|
Risk Assessment | 1 | 2017 | 2261 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2013 | 1019 | 0.020 |
Why?
|
Oxadiazoles | 1 | 2009 | 46 | 0.020 |
Why?
|
Precancerous Conditions | 1 | 2010 | 196 | 0.020 |
Why?
|
Cardiac Myosins | 1 | 2008 | 18 | 0.020 |
Why?
|
Exercise Test | 1 | 2010 | 164 | 0.020 |
Why?
|
Phorbol Esters | 1 | 2008 | 22 | 0.020 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2009 | 28 | 0.020 |
Why?
|
Ventilator-Induced Lung Injury | 1 | 2009 | 31 | 0.020 |
Why?
|
Adenoviridae | 1 | 2010 | 345 | 0.020 |
Why?
|
Protein Kinase C beta | 1 | 2008 | 16 | 0.020 |
Why?
|
Acute Lung Injury | 1 | 2009 | 60 | 0.020 |
Why?
|
Leukocidins | 1 | 2008 | 3 | 0.020 |
Why?
|
Adolescent | 2 | 2012 | 8981 | 0.020 |
Why?
|
Pneumonia, Staphylococcal | 1 | 2008 | 5 | 0.020 |
Why?
|
Inhibitory Concentration 50 | 1 | 2008 | 64 | 0.020 |
Why?
|
Chemokine CXCL1 | 1 | 2008 | 9 | 0.020 |
Why?
|
Chemokine CXCL2 | 1 | 2008 | 16 | 0.020 |
Why?
|
Exotoxins | 1 | 2008 | 20 | 0.020 |
Why?
|
Research Design | 1 | 2012 | 594 | 0.020 |
Why?
|
Myosin Heavy Chains | 1 | 2008 | 88 | 0.020 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2008 | 38 | 0.020 |
Why?
|
Rats, Inbred Dahl | 1 | 2008 | 8 | 0.020 |
Why?
|
Complement C1q | 1 | 2008 | 10 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2011 | 296 | 0.020 |
Why?
|
Curriculum | 1 | 2013 | 539 | 0.020 |
Why?
|
Transforming Growth Factor beta3 | 1 | 2008 | 16 | 0.020 |
Why?
|
Gene Deletion | 1 | 2009 | 329 | 0.020 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2008 | 121 | 0.020 |
Why?
|
Macrophages, Alveolar | 1 | 2008 | 55 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2009 | 236 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 894 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2009 | 286 | 0.020 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2008 | 33 | 0.020 |
Why?
|
Methylprednisolone | 1 | 2007 | 66 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 81 | 0.020 |
Why?
|
Virulence Factors | 1 | 2008 | 108 | 0.020 |
Why?
|
Students, Medical | 1 | 2013 | 384 | 0.020 |
Why?
|
Virulence | 1 | 2008 | 271 | 0.020 |
Why?
|
Phenylurea Compounds | 1 | 2008 | 114 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2008 | 331 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2010 | 1219 | 0.020 |
Why?
|
Ultrasonography | 1 | 2010 | 695 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2008 | 256 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2008 | 222 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2010 | 645 | 0.020 |
Why?
|
Antigens, CD | 1 | 2008 | 458 | 0.020 |
Why?
|
Inflammation | 1 | 2012 | 920 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 189 | 0.020 |
Why?
|
RNA Interference | 1 | 2008 | 369 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2009 | 579 | 0.020 |
Why?
|
Brain Neoplasms | 1 | 2012 | 763 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2012 | 2379 | 0.020 |
Why?
|
Blotting, Western | 1 | 2008 | 782 | 0.020 |
Why?
|
Calcium | 1 | 2011 | 1156 | 0.020 |
Why?
|
Risk Factors | 1 | 2016 | 5417 | 0.020 |
Why?
|
Adrenal Gland Diseases | 1 | 2005 | 13 | 0.020 |
Why?
|
Erlotinib Hydrochloride | 1 | 2006 | 90 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 879 | 0.020 |
Why?
|
United States | 1 | 2018 | 6672 | 0.020 |
Why?
|
Adrenal Glands | 1 | 2005 | 76 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2010 | 1805 | 0.020 |
Why?
|
Cell Line | 1 | 2010 | 2468 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2010 | 1135 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2007 | 352 | 0.020 |
Why?
|
Genotype | 1 | 2010 | 1851 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 683 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2010 | 1801 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2011 | 1313 | 0.020 |
Why?
|
Quality of Life | 1 | 2012 | 1585 | 0.020 |
Why?
|
Hemorrhage | 1 | 2005 | 268 | 0.010 |
Why?
|
Neurons | 1 | 2012 | 1546 | 0.010 |
Why?
|
Heart Ventricles | 1 | 2008 | 760 | 0.010 |
Why?
|
Child | 1 | 2012 | 6927 | 0.010 |
Why?
|
Young Adult | 1 | 2012 | 5976 | 0.010 |
Why?
|